Key Takeaways GLP-1 medications produce rapid weight loss that depletes two physical support structures simultaneously: the subcutaneous fat scaffold that provides volumetric shape, and the lean muscle beneath it that provides mechanical support
But while the world is going to just continue to yell about the weight loss numbers, I want to discuss the fact that this drug seems to be about as close to a metabolic fix it all, unlike anything weve seen before
A quick check with other clinics in Singapore showed that demand has also gone up
This physical fullness works alongside the medications chemical satiety signals, helping to reduce cravings and quiet the constant "food noise." The slow-digesting carbs in these grains also provide a steady energy source, avoiding the blood sugar spikes that can lead to hunger
And so, scientists like Murielle Vniant-Ellison and others in our organization built a monoclonal antibody that would inhibit the GIP receptor, recognizing that GLP one agonism can also confer favorable physiology and obesity and related conditions, we have appended two GLP-1 peptides to this antibody. Amgen bought deCode Genetics back in 2012
Can females use insulin